Estradiol; Progesterone Patent Expiration
Estradiol; Progesterone is Used for relieving menopause symptoms, including vasomotor symptoms. It was first introduced by Mayne Pharma Llc
Estradiol; Progesterone Patents
Given below is the list of patents protecting Estradiol; Progesterone, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Bijuva | US10052386 | Progesterone formulations | Nov 21, 2032 | Mayne Pharma |
Bijuva | US10206932 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Bijuva | US10639375 | Progesterone formulations | Nov 21, 2032 | Mayne Pharma |
Bijuva | US10675288 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Bijuva | US10806740 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Bijuva | US11033626 | Progesterone formulations having a desirable pk profile | Nov 21, 2032 | Mayne Pharma |
Bijuva | US11103513 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Bijuva | US11103516 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Bijuva | US11110099 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Bijuva | US11166963 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Bijuva | US11529360 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Bijuva | US11793819 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Bijuva | US11865179 | Progesterone formulations having a desirable PK profile | Nov 21, 2032 | Mayne Pharma |
Bijuva | US8633178 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Bijuva | US8846648 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Bijuva | US8846649 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Bijuva | US8933059 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Bijuva | US8987237 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Bijuva | US8993548 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Bijuva | US8993549 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Bijuva | US9006222 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Bijuva | US9114145 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Bijuva | US9114146 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Bijuva | US9301920 | Natural combination hormone replacement formulations and therapies | Nov 21, 2032 | Mayne Pharma |
Estradiol; Progesterone's Family Patents

Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List